Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
Get 40% Off
/Free Sign Up
 0
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks
Close

Orientbio (002630)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create New Watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
526 -6    -1.13%
26/04 - Closed. Currency in KRW ( Disclaimer )
  • Volume: 246,751
  • Bid/Ask: 525 / 526
  • Day's Range: 496 - 533
Type:  Equity
Market:  South Korea
ISIN:  KR7002630002 
Orientbio 526 -6 -1.13%

002630 Balance Sheet

 
Assess the latest Orientbio balance sheet. Review the company's financial position, assess their current assets, liabilities and shareholder equity across the most recent periods (either quarterly or annually).

Even more advanced 002630 Annual Report data, financial summaries and charts are available for Orientbio investors with their own InvestingPro account.
AnnualQuarterly
InvestingPro Advanced Balance Sheet
Collapse All
Period Ending: 2021
31/12
 2021
30/09
 2021
30/06
 2021
31/03
Total Current Assets 39833.72 29144.34 30376.4 29060.49
Cash and Short Term Investments 11601.88 4574.76 7654.72 10940.02
Cash - - - -
Cash & Equivalents 11601.88 4574.76 7654.72 10940.02
Short Term Investments - - 3307.6 -
Total Receivables, Net 13684.92 13011.83 12591.63 9420.99
Accounts Receivables - Trade, Net 11208 10529.34 10675.09 7461.29
Total Inventory 7500.39 8351.92 7353.3 5927.58
Prepaid Expenses - - 1976.75 1971.89
Other Current Assets, Total 7046.53 3205.82 800 2771.89
Total Assets 82129.89 71916.98 71943.67 71518.51
Property/Plant/Equipment, Total - Net 30935.8 31551.32 30342.25 31321.04
Property/Plant/Equipment, Total - Gross - - - 71241.84
Accumulated Depreciation, Total - - - -39920.8
Goodwill, Net - - - -
Intangibles, Net 467.85 469.65 471.76 474.53
Long Term Investments 5572.56 5664.26 5716.18 5650.21
Note Receivable - Long Term 2964.23 2962.05 2949.31 2962.05
Other Long Term Assets, Total 2355.72 2125.36 2087.77 2050.19
Other Assets, Total - - - -
Total Current Liabilities 22118.81 11291.83 11066 15230.44
Accounts Payable 1091.22 1178.21 490.91 759.97
Payable/Accrued - - - -
Accrued Expenses - - 341.08 370.14
Notes Payable/Short Term Debt 4800 4900 4900 4900
Current Port. of LT Debt/Capital Leases 939.27 539.71 943.27 2111.59
Other Current liabilities, Total 15288.32 4673.91 4390.74 7458.87
Total Liabilities 29305.99 19552.26 19609.37 22973.56
Total Long Term Debt 1531.46 2063.42 1793.72 1095.13
Long Term Debt 1230 1230 1230 -
Capital Lease Obligations 301.46 833.42 563.72 1095.13
Deferred Income Tax - - - -
Minority Interest - - - 0.27
Other Liabilities, Total 5655.72 6197.01 6749.65 6647.72
Total Equity 52823.9 52364.72 52334.3 48544.94
Redeemable Preferred Stock, Total - - - -
Preferred Stock - Non Redeemable, Net - - - -
Common Stock, Total 59291.5 59291.5 59291.5 59286.02
Additional Paid-In Capital 9530.09 9530.09 8790.71 9514.14
Retained Earnings (Accumulated Deficit) -16210.65 -16652.55 -15932.29 -19730.74
Treasury Stock - Common - - - -
ESOP Debt Guarantee - - - -
Unrealized Gain (Loss) 850.38 850.38 850.38 850.38
Other Equity, Total -637.42 -654.7 -666 -1374.86
Total Liabilities & Shareholders' Equity 82129.89 71916.98 71943.67 71518.51
Total Common Shares Outstanding 118.57 118.57 118.57 118.56
Total Preferred Shares Outstanding - - - -
* In Millions of (except for per share items)
InvestingPro
Go to Dashboard InvestingPro

Unlock access to over 1000 metrics with InvestingPro

View advanced insights on the balance sheet, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.

 
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

002630 Price Commentary

Write your thoughts about Orientbio
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Black Bird
Black Bird Aug 14, 2020 8:45
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Biotech market will recover and will flourish for the coming years, but also will expected to be very competitive because of easy entry and investors attention catching. So many research and researchers out there waiting for opportunities. But, a company needs to be sustain these coming events, and this one has issues in its operations that need immediate action.
Reply
0 0
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Continue with Google
or
Sign up with Email